{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T23:08:20Z","timestamp":1760828900490,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.ecl.2016.09.008","type":"journal-article","created":{"date-parts":[[2016,11,27]],"date-time":"2016-11-27T23:15:12Z","timestamp":1480288512000},"page":"193-206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Combined Pharmacologic Therapy in Postmenopausal Osteoporosis"],"prefix":"10.1016","volume":"46","author":[{"given":"Yang","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dona L.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothy S.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ecl.2016.09.008_bib1","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician's guide to prevention and treatment of osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.ecl.2016.09.008_bib2","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMcp1513724","article-title":"Clinical practice. postmenopausal osteoporosis","volume":"374","author":"Black","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.ecl.2016.09.008_bib3","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1172\/JCI27071","article-title":"Pathogenesis of osteoporosis: concepts, conflicts, and prospects","volume":"115","author":"Raisz","year":"2005","journal-title":"J\u00a0Clin Invest"},{"issue":"12","key":"10.1016\/j.ecl.2016.09.008_bib4","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nrendo.2013.179","article-title":"The role of estrogen and androgen receptors in bone health and disease","volume":"9","author":"Manolagas","year":"2013","journal-title":"Nat Rev Endocrinol"},{"issue":"21","key":"10.1016\/j.ecl.2016.09.008_bib5","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMct1004903","article-title":"Bisphosphonates for osteoporosis","volume":"363","author":"Favus","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.ecl.2016.09.008_bib6","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMra053077","article-title":"Bone quality\u2013the material and structural basis of bone strength and fragility","volume":"354","author":"Seeman","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.ecl.2016.09.008_bib7","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1056\/NEJM199404143301508","article-title":"Hormonal treatment of postmenopausal women","volume":"330","author":"Belchetz","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ecl.2016.09.008_bib8","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.ecl.2016.09.008_bib9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.7326\/M14-0317","article-title":"Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review","volume":"161","author":"Crandall","year":"2014","journal-title":"Ann Intern Med"},{"issue":"9041","key":"10.1016\/j.ecl.2016.09.008_bib10","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.ecl.2016.09.008_bib11","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ecl.2016.09.008_bib12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ecl.2016.09.008_bib13","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J\u00a0Bone Miner Res"},{"issue":"14","key":"10.1016\/j.ecl.2016.09.008_bib14","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ecl.2016.09.008_bib15","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.ecl.2016.09.008_bib16","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra067395","article-title":"Mechanisms of anabolic therapies for osteoporosis","volume":"357","author":"Canalis","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.ecl.2016.09.008_bib17","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"9077","key":"10.1016\/j.ecl.2016.09.008_bib18","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","article-title":"Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis","volume":"350","author":"Lindsay","year":"1997","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ecl.2016.09.008_bib19","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1359\/jbmr.2001.16.5.925","article-title":"Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal","volume":"16","author":"Cosman","year":"2001","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2016.09.008_bib20","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/bonekey.2014.13","article-title":"Combination therapy for osteoporosis: a reappraisal","volume":"3","author":"Cosman","year":"2014","journal-title":"Bonekey Rep"},{"issue":"2","key":"10.1016\/j.ecl.2016.09.008_bib21","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1359\/JBMR.051020","article-title":"Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy","volume":"21","author":"Ste-Marie","year":"2006","journal-title":"J\u00a0Bone Miner Res"},{"issue":"11","key":"10.1016\/j.ecl.2016.09.008_bib22","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1359\/JBMR.050714","article-title":"Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial","volume":"20","author":"Deal","year":"2005","journal-title":"J\u00a0Bone Miner Res"},{"issue":"4","key":"10.1016\/j.ecl.2016.09.008_bib23","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1210\/jc.2009-1703","article-title":"Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis","volume":"95","author":"Finkelstein","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"13","key":"10.1016\/j.ecl.2016.09.008_bib24","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.ecl.2016.09.008_bib25","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ecl.2016.09.008_bib26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"issue":"1","key":"10.1016\/j.ecl.2016.09.008_bib27","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/jbmr.1716","article-title":"Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density","volume":"28","author":"Muschitz","year":"2013","journal-title":"J\u00a0Bone Miner Res"},{"issue":"10","key":"10.1016\/j.ecl.2016.09.008_bib28","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1210\/jc.2008-2719","article-title":"Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent","volume":"94","author":"Cosman","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2016.09.008_bib29","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa050157","article-title":"Daily and cyclic parathyroid hormone in women receiving alendronate","volume":"353","author":"Cosman","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"9886","key":"10.1016\/j.ecl.2016.09.008_bib30","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"issue":"9999","key":"10.1016\/j.ecl.2016.09.008_bib31","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ecl.2016.09.008_bib32","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1210\/jc.2016-1160","article-title":"Effects of two years of teriparatide, denosumab, or both on bone microarchitecture and strength (DATA-HRpQCT study)","volume":"101","author":"Tsai","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.ecl.2016.09.008_bib33","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1210\/jc.2015-1541","article-title":"Comparative resistance to teriparatide-induced bone resorption with denosumab or alendronate","volume":"100","author":"Tsai","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.ecl.2016.09.008_bib34","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1210\/jc.2013-3795","article-title":"Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis","volume":"99","author":"Mandema","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852916301013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852916301013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:40:56Z","timestamp":1760175656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852916301013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0889852916301013"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2016.09.008","relation":{},"ISSN":["0889-8529"],"issn-type":[{"type":"print","value":"0889-8529"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined Pharmacologic Therapy in Postmenopausal Osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2016.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}